Grants

Defining the signal transduction pathways of Chimeric Antigen Receptors (CAR) as a means to increase the efficacy of CAR T cell therapy for pediatric leukemias (2019)

CD99 targeting CAR T cells as a novel therapy for H3K27M mutant DIPG (2019)

Engineering and testing an innovative logic-gated CAR T cell against the most aggressive pediatric brain tumor, H3K27M mutant DIPG (2020)

Targeting mitochondrial regulator MCJ to enhance CD8 immune response (2020)

Analysis of Chimeric Antigen Receptor (CAR) signal transduction as a means to rationally optimize novel CAR T cell therapies for acute myelogenous leukemias (2020)

Engineering logic-gated CD99 CARs to selectively target H3K27M-DIPG tumor cells and protect normal cells (2020)

Regulating mitochondrial metabolism in CD8 cells to improve CAR-T immunotherapy (2020)

Development of Novel Chimeric Antigen Receptors to Target Antigen-Low Pediatric Leukemia (2021)

Novel CAR T cell therapies targeting metastatic Ewing Sarcoma (2021)

Multi-antigen specific CAR T cells as a novel therapy for relapsed/refractory AML (2021)

Overcoming the Challenges of Metastatic Ewing Sarcoma Using a Novel Gene-edited CAR-T Cell Therapy (2021)

Using logic-gated CAR-T cells and combination therapies to increase the efficacy and safety of DIPG treatment (2022)

Escape from CAR T cell surveillance through lineage plasticity (2022)

Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response (2022)